



Deposited via The University of Leeds.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/203779/>

Version: Accepted Version

Article:

de Ligt, K.M., de Rooij, B.H., Koppert, L.B. et al. (Cover date: December 2023) Patient-reported outcome measures to improve the care continuum for patients with metastatic breast cancer: opportunities and implications for nursing practice. *Seminars in Oncology Nursing*, 39 (6). 151510. ISSN: 0749-2081

<https://doi.org/10.1016/j.soncn.2023.151510>

© 2023, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Patient-reported outcome measures to improve care for patients with metastatic breast cancer: opportunities and implications for nursing practice

K.M. de Ligt^a, B.H. de Rooij^b, L.B. Koppert^c, L.V. van de Poll-Franse^d, G. Velikova^e, F. Cardoso^f

^aDivision of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
K.d.ligt@nki.nl

^bDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation, Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands;

Department of Medical and Clinical Psychology, Center of Research on Psychological and Somatic Disorders (CoRPS), Tilburg University, Warandelaan 2, 5037 AB, Tilburg, the Netherlands.
B.derooij@iknl.nl

^cDepartment of Surgical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
l.koppert@erasmusmc.nl

^dDivision of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.

Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands;

Department of Medical and Clinical Psychology, Center of Research on Psychological and Somatic Disorders (CoRPS), Tilburg University, Warandelaan 2, 5037 AB, Tilburg, the Netherlands.
l.vd.poll@nki.nl

^eLeeds Institute of Medical Research at St James's, University of Leeds, St James's University Hospital, Woodhouse Lane, LS2 9JT, Leeds, United Kingdom.

Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, St James's University Hospital, Beckett St, Harehills, LS9 7LP, Leeds, United Kingdom.
g.velikova@leeds.ac.uk

^fBreast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Avenida Brasília s/n, 1400-038, Lisbon, Portugal.
Fatimacardoso@fundacaochampalimaud.pt

Corresponding author:

Kelly de Ligt, PhD.

Netherlands Cancer Institute, Division of Psychosocial Research and Epidemiology

PO Box 90203, 1006 BE Amsterdam

e-mail: k.d.ligt@nki.nl | telephone: +31 20 512 9111

Abstract

Objectives: The Advanced Breast Cancer (ABC) Global Alliance has identified ten urgent and actionable goals for the decade between 2015 and 2025 to achieve substantial improvement in the lives of patients living with ABC, including metastatic breast cancer (MBC). Enhancements for MBC patients are needed for health-related quality of life (HRQoL), research, quality of care, and survival. We explore the potential of patient reported outcome measures (PROMs) in addressing these gaps and aim to describe opportunities and current initiatives for improving MBC care through PROMs.

Data sources: Recent literature on MBC and PROMs is described narratively.

Conclusion: Based on findings in the literature, we believe PROMs have the potential to make valuable contributions to seven of the ten goals described: 1) improving HRQoL; 2) enhancing the understanding of MBC through the collection of high quality data; 3) contributing to increasing survival; 4) supporting communication between healthcare providers (HCPs) and MBC patients; 5) increasing patients' awareness and referral to non-clinical support services; 6) encouraging improvements in access to healthcare; 7) supporting meeting the informational needs of patients with MBC.

Implications for Nursing Practice: Maximizing the benefits of PROMs requires effective implementation strategies. As nurses and nurse practitioners are at the forefront of care, they can offer a comprehensive understanding of patients' needs and play a crucial role in facilitating the integration of PROMs into routine care for MBC patients and ultimately optimizing patient outcomes.

Keywords: Metastatic breast cancer, health-related quality of life, patient-reported outcome measures, quality of care, advanced breast cancer, ABC global alliance

With yearly 2.2 million new patients, breast cancer is the most commonly diagnosed cancer worldwide [1]. Although it is the leading cause of cancer-related deaths in women (685,000 deaths in 2020 [1]), the five-year survival rates are generally high (99% for localized, 83-86% for regional breast cancer) [2, 3]. Eventually, 20-30% of these patients will develop metastatic breast cancer (MBC) [4, 5]. In high income countries, 5-10% of patients are already diagnosed with de novo MBC; in low-middle income countries, this can reach percentages as high as 60-80% [3, 6]. MBC remains incurable, albeit treatable, and survival rates remain poor (five-year survival: 25-34%; estimated median survival: 2-3 years [3, 5, 7]). The last few years, survival rates have substantially improved for two of three main MBC subtypes, HER2-positive and ER+/HER2-negative MBC, which now have a median OS of about 5 years [8, 9]. Although MBC treatment is primarily focused on extending survival, there is always a trade-off with managing adverse effects and health-related quality of life (HRQoL) [10], because MBC and its treatment often lead to adverse effects that affect HRQoL [11]. Furthermore, patients need to confront the reality that they will not be cured [5, 12, 13], and because MBC progresses, decisions are time-sensitive and outcomes uncertain [5, 14]. Disease control and progression, fear and hope, and fluctuations in HRQoL alternate constantly [14, 15]. As HRQoL is also associated with overall survival [16], optimizing HRQoL in MBC patients is vital.

There is an urgent need for improvement of care for MBC patients [14, 15, 17, 18]. The Advanced Breast Cancer (ABC) Global alliance [18], a non-profit multi-stakeholder organization that aims to improve the lives of all patients living with ABC worldwide, published the ABC Global Charter in 2017 and updated it in 2022. The charter was based on the findings of a comprehensive report, the Decade Report [5], developed through multi-stakeholder discussions, involving patients, patient advocates, healthcare providers, commercial partners, and policymakers. The ABC Global Charter defines 10 urgent and actionable goals for the decade between 2015 and 2025 to achieve substantial improvement in the lives of patients living with ABC (**Figure 1**), which include enhancing HRQoL, improving survival, ensuring quality of care through better healthcare access, communication, and information provision, and boosting research. In their commentary on metastatic cancer survivorship care, Lai-Kwon et al. [15] propose to expand the survivorship care agenda beyond curatively treated patients to include those with metastatic cancer. Like the ABC Global Alliance, they pose the understanding of the metastatic cancer survivorship experience is incomplete, communication and

care coordination should be improved, and healthcare and healthcare practitioners' (HCPs) capacities should be aligned with metastatic cancer patients' needs.

Both only briefly acknowledge patient reported outcome measures (PROMs) as a means of improvement [15, 18]. PROMs are instruments that capture measurements of health status directly from the patient, without the interpretation of third parties [19]. Initially developed to measure HRQoL in trials and research, PROMs are now implemented in routine clinical practice. Patients typically complete PROMs electronically as part of their care, and receive feedback on their scores from their HCP during clinical consultations or directly via patient dashboards or tools [20, 21]. PROMs can be used for screening, monitoring, treatment decision-making, and to facilitate communication about HRQoL [20, 22]. Nurses play a vital role in the implementation and utilization of PROMs, as they can actively engage with patients, using PROMs as a basis for discussion and shared-decision making. We believe that PROMs could play an important role in achieving improvements in HRQoL, research, quality of care, and survival for MBC patients. In this opinion paper, we describe opportunities and initiatives for improving MBC care through PROMs following the 10 goals of the ABC Global Charter.

PROMs could promote health-related quality of life

PROMs in clinical practice could improve HRQoL (**goal 3**). In a Cochrane systematic review, Gibbons et al. [23] outline the effectiveness of PROMs in clinical practice in improving oncology care processes and/or outcomes, summarizing 116 randomized trials conducted before 2020. PROMs were found to improve HRQoL (standardized mean difference (SMD): 0.15, 95% confidence interval (CI) 0.05-0.26; 11 studies; 2687 participants). Notably, the study by Basch et al. in metastatic cancer reported a SMD of 0.31 (CI: 0.12-0.50) patients [24, 25]). After six months, significantly more patients who completed PROMs registered clinically meaningful HRQoL improvements compared to usual care (21% vs. 11%; $p < 0.001$) [25]. Conducted after 2020, the PRO-TECT trial provisionally concluded that after 3 months, symptom control (on a scale 0-100: PRO: 77.67 to 80.03 points; usual care: 76.75 to 76.55 points; mean difference, 2.56 [95%-CI, 0.95-4.17]; $P = .002$) and HRQOL (PRO: 78.11 to 80.03 points; usual care: 77.00 to 76.50 points; mean difference, 2.43 [95%-CI, 0.90-3.96]; $P = .002$) were significantly improved in metastatic cancer patients who regularly completed PROMs compared to usual care [26].

These effects rely on proper implementation of PROMs. It is crucial to ensure regular completion and participation, which was proven achievable in research settings, even in relatively ill patients or those

with limited digital experience [26, 27]. Partially, limited utilization of PROMs in MBC care could be attributed to inadequate measurement tools that do not fully capture issues specifically relevant for MBC patients. Therefore, the European Organisation for Research and Treatment of Cancer (EORTC) and the ABC Global Alliance are developing an MBC-specific PROM [28], which is expected to be finalized in 2025.

With dedicated attention and resources, implementation outside research settings is achievable [20, 29, 30]. Nurses emphasized the need for a shared strategy on how and towards what goal they should integrate PROMs into their workflows, considering time constraints and prioritization of PROMs within their responsibilities. Furthermore, outcomes were not always easily accessible in electronic health records (EHR) [31], adding to the time constraints nurses face. Streamlining documentation processes and ensuring easy access to PROM data can help address these constraints.

Research supported by PROMs data collection

The understanding of MBC could be enhanced by increasing the collection of high quality data (**goal 2**), as burden and unmet needs of MBC patients are difficult to measure due to lack of accurate, population-based data. Therefore, it is essential that HRQoL, PROMs, and patient-reported experience measures (PREMs) are systematically collected in clinical research and practice [17, 18]. Towards systemic data collection, the Health Outcomes Observatory initiative [32] recently developed an MBC-specific core outcome set (COS). This is a sample of carefully selected and validated measurements for standardized measurement of disease and treatment, which can include PROMs. It comprises comprehensive recommendations for standardized tracking of survival and disease progression, patient, disease, and treatment characteristics, and adverse events and HRQoL. It followed from consensus reached with 141 international stakeholders in a modified Delphi procedure, in which especially the opinion of the 45 included patients and patient advocates weight in [33]. Specifically, it includes 26 outcomes covering aspects of HRQoL that can be measured with the EORTC MBC-specific PROM, such as daily functioning, ability to work, psychosocial functioning, emotional functioning, relationships, and sexual functioning. This ensures a holistic and multidisciplinary approach to evaluate patients' well-being, a view already practiced by nurses [21]. To boost implementation, the International Consortium for Health Outcomes Measurement (ICHOM) accredited the MBC COS.

Increased survival through PROM symptom monitoring

PROM symptom monitoring during treatment could contribute to increasing survival of MBC patients (**goal 1**). In a systematic literature review, Lizán et al. [34] summarized evidence of trials on PROM symptom monitoring in clinical cancer care in Europa, North America, and Australia between 2011-2021. Eight of 16 identified reports included metastatic cancer patients; 4 included large populations of MBC patients. Thirteen studies compared electronic PROM symptom monitoring to regular care (i.e. where patients discussed symptoms with HCPs during clinical consultations). Significantly improved survival was reported in studies about metastatic cancer: overall survival benefit: 6% and 5.2 months [24, 25]; overall survival benefit: 5.5% after one year of survival [35]. These results likely stem from improved symptom notation (risk ratio (RR) 1.73, 95% CI 1.44-2.08; 21 studies; 7223 participants), disease control (RR 1.25, 95% CI 1.10-1.41; 14 studies; 2806 participants) [23], early detection of tumor recurrence, and prolonged chemotherapy use [34].

Extrapolation of trial results to clinical practice should be done with caution [34]. Studying the effects of PROM symptom monitoring in routine care would be worthwhile: this may be especially important for patients undergoing continuous treatment [35], which typically applies to MBC patients. Although doubling median overall survival, as aimed by the ABC global charter, relies on the development of more effective treatments and the wider accessibility to existent ones, a contribution of several extra months of survival with improved HRQoL is substantial for patients with a median survival of two to three years [3, 5, 7]. Even if effects for individuals are small, they may have a profound effect on care for the MBC population as a whole [36].

The MBC COS recommends measurement of 24 adverse effects during treatment cycles [33]. More than any other HCP, nurses spend time with their patients during treatment administration. This creates opportunities to discuss PROMs with their patients: as illustrated by Pereira et al. [37], 85% of nurses compared to 61% of physicians frequently discussed PROMs with patients using a symptom monitoring system implemented in 14 hospitals in Canada.

PROMs towards improvements in quality of care

Effective communication between HCPs and patients is critical for metastatic cancer patients [12, 15]. To improve this aspect of care, the ABC proposes communication training for HCPs and patients (**goal 5**). Hart et al. [17] systematically summarized 81 studies published between 2002 and 2022 about the

unmet supportive care needs of cancer patients. Forty-five percent (26–67%) of MBC patients reported an unmet health system and information need. In advanced solid cancer patients, 35% lacked information about 'things you can do to stay well', and 31% reported lack of one appointed HCP to talk about all aspects of your condition, treatment, and follow-up. PROMs in clinical practice has shown potential in improving patient-physician communication (SMD 0.36, 95% CI 0.21-0.52; 5 studies; 658 participants) [23]. However, a crucial element here is the feedback of results to patients [38]. HCPs require training on how to interpret and communicate about PROMs effectively and use these to inform patient management [20]. While this requires more attention [20], several training programs have been developed and tested that could be disseminated to hospital practice [39, 40].

PROMs can support the referral to and awareness about (non-clinical) supportive care services (**goal 7**). As reported in a Dutch survey and UK interview study among MBC patients, patients were unaware of or did not receive the supportive care they needed [14, 41]. Nurses acknowledged that PROMs offer valuable and personalized information about their patients, supporting identification of supportive care needs [31, 42].

PROMs generates outcome data that are urgently needed for health policymaking [15, 22] The MBC COS contributes to this by measuring patients' access to healthcare and the relationship between the patient and the medical team, both aimed at improving quality of care by encouraging that all MBC patients have access to care from a multidisciplinary team (**goal 4**), which is crucial in addressing the complex needs of advanced cancer patients [17].

Finally, PROMs data is an important resource for patient education, decision aids, and information provision [22]. Presentation of PROMs aligned with patients' needs and preferences [43] can support meeting the informational needs of patients with MBC (**goal 6**).

Discussion

This work presents how PROMs could contribute to the fulfillment of many of the ABC Global Charter goals and, by doing so, improve care for MBC patients. This includes: 1) improving HRQoL; 2) enhancing the understanding of MBC through high quality data collection; 3) contributing to increasing survival; 4) supporting HCP-patient communication; 5) assisting patients' awareness and referral to

supportive care; 6) promoting access to healthcare; 7) supporting the informational needs of MBC patients.

Additionally to the development of new, more effective and/or less toxicity therapeutic agents, implementing PROMs in clinical practice is an opportunity already at hand. Importantly, new agents for MBC are substantially more expensive than PROMs [44]. Although annual costs of PROMs symptom monitoring are higher than usual care, these are counterbalanced by the survival benefits [34]. PROMs can contribute to value-based healthcare (VBHC), by ensuring patients receive care they value and get ‘the right care in the right place’ through better understanding of their needs and preferences. Nurses play an important part in VBHC: they work close with the patient and are therefore strong advocates of patient-centered care, which could facilitate bottom-up restructuring of care [45]. Specialized nurses, in particular, possess specialized knowledge that enhances their understanding of patient needs, supporting the shift towards patient-centered care and evolving focus from “living after cancer” to “living with cancer” [15].

Even after the introduction of new therapies for MBC patients, PROMs remain valuable. Managing new therapies, like immunotherapies and targeted therapies, poses unique new challenges linked to new and sometimes unexpected side effects, on top of managing uncertainty and fear of cancer progression in a new treatment setting [15]. That is, anxiety, stress, depression, and decreased HRQoL and social support are associated with unmet care needs in patients with solid advanced tumors [17]. Managing these symptoms, which are inherently present in the uncertain disease trajectories of MBC patients, will therefore always be important.

The care of metastatic cancer patients is marked by increasing inequalities worldwide between and within countries [15]. PROMs may unfortunately add to the inequalities: studies presenting trials and clinical practice examples of mainly administered electronically PROMs [34] were generally conducted in high income countries [20, 23, 34]. Electronic PROMs may not be easy to implement in low-middle income countries, creating an even larger lag to high income countries. Furthermore, older MBC patients, and patients with lower HRQoL and less technical skills frequently report barriers for electronic PROM completion [46]. This widens the ‘digital divide’ between those who can and cannot participate in and thus benefit from eHealth applications [47]. Efforts should be made to include all patients, regardless of literacy, health literacy, digital literacy, and access to technology and care [48].

Further research is required to establish real-world evidence to complement research in trial settings, cost-effectiveness [34], and the mechanisms through which PROMs work in different clinical contexts [22, 23]. Large cluster-randomized trials of PROMs remain necessary, as current studies display a considerable variation in participants, settings, interventions, and measures [23].

PROMs implementation requires investments in terms of efforts, time, and resources. It comprises more than building an electronic portal for PROMs completion, and should be supported by a technical briefing, technical telephone support, and on-site support services [46]. Providing feedback of the results to patients by HCPs is crucial. By ensuring that all involved HCPs have access to a patient's PROMs, including nurses and nurse practitioners, a more multidisciplinary and holistic perspective can be provided. Nurses could play a vital role in successful PROMs implementation, as they work at the forefront of patient care.

Acknowledgements: -

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of interest:

BdR, LK and LvdPF received funding within the Innovative Medicines Initiative 2 Joint Undertaking Health Outcomes Observatories (H2O) under grant agreement No 945345-2.

GV received honoraria from Pfizer, Novartis, Eisai; consultancy fees (for advisory boards) from AstraZeneca, Roche, Novartis, Pfizer, Seagen, Eisai, Sanofi; institutional grants from Pfizer, EORTC, Breast Cancer Now, Yorkshire Cancer Research (all outside the submitted work).

The other authors declare no conflicts of interest related to the work presented in this manuscript.

Authorship:

Conceptualization: KdL, BdR, LK, LvdPF, GV, FC;

Roles/Writing - original draft: KdL, BdR;

Writing - review and editing: LK, LvdPF, GV, FC.

All authors have approved the submitted version of the manuscript

References

1. Sung H, et al., *Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries*. CA Cancer J Clin, 2021. **71**(3): p. 209-249.
2. Allemani C, et al., *Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries*. The Lancet, 2018. **391**(10125): p. 1023-1075.
3. National Cancer Institute, *National Cancer Institute: SEER stat fact sheets: Female breast cancer*. 2020.
4. O'Shaughnessy J, *Extending survival with chemotherapy in metastatic breast cancer*. Oncologist, 2005. **10**: p. 20-29.
5. Cardoso F, et al., *Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015)*. Breast Cancer Res Treat, 2018. **39**(131e8).
6. Unger-Saldaña K, *Challenges to the early diagnosis and treatment of breast cancer in developing countries*. World J Clin Oncol., 2014. **5**(3): p. 465-477.
7. Deluche E, et al., *Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016*. European Journal of Cancer, 2020. **129**: p. 60-70.
8. Swain SM, et al., *Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer*. New England Journal of Medicine, 2015. **372**(8): p. 724-734.
9. Hortobagyi GN, et al., *Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer*. New England Journal of Medicine, 2022. **386**(10): p. 942-950.
10. Cardoso F, et al., *5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)*. Ann Oncol., 2020. **31**(12): p. 1623-1649.
11. Reed E, et al., *Quality of life and experience of care in women with metastatic breast cancer: a cross-sectional survey*. J Pain Symptom Manage, 2012. **43**(4): p. 747-58.
12. Danesh M, et al., *Informational needs of patients with metastatic breast cancer: what questions do they ask, and are physicians answering them?* J Cancer Educ., 2014. **29**(1): p. 175-180.
13. Ginter AC, *"The day you lose your hope is the day you start to die": Quality of life measured by young women with metastatic breast cancer*. Journal of Psychosocial Oncology, 2020. **38**(4): p. 418-434.
14. Reed E and Corner J, *Defining the illness trajectory of metastatic breast cancer*. BMJ Support Palliat Care, 2015. **5**(4): p. 358-65.
15. Lai-Kwon J, et al., *Evolving Landscape of Metastatic Cancer Survivorship—Reconsidering Clinical Care, Policy, and Research Priorities for the Modern Era*. Journal of Clinical Oncology, 2023. **0**(0): p. JCO.22.02212.
16. Bjelic-Radisic V, et al., *Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial*. BMC Cancer, 2020. **20**(1): p. 392.
17. Hart NH, et al., *Unmet supportive care needs of people with advanced cancer and their caregivers: A systematic scoping review*. Crit Rev Oncol Hematol, 2022. **176**: p. 103728.
18. Advanced breast cancer (ABC) global alliance. *Advanced breast cancer (ABC) global charter*. 2022; Available from: <https://www.abcgloballiance.org/abc-hub#global-charter>.
19. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, *Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance*. Health Qual Life Outcomes, 2006. **4**: p. 79.
20. Anatchkova, M., et al., *Exploring the implementation of patient-reported outcome measures in cancer care: need for more real-world evidence results in the peer reviewed literature*. Journal of Patient-Reported Outcomes, 2018. **2**(1): p. 64.

21. Greenhalgh J, et al., *How do patient reported outcome measures (PROMs) support clinician-patient communication and patient care? A realist synthesis*. Journal of Patient-Reported Outcomes, 2018. **2**(1): p. 42.
22. Greenhalgh J, *The applications of PROs in clinical practice: what are they, do they work, and why?* Qual Life Res, 2009. **18**: p. 115–123.
23. Gibbons C, et al., *Routine provision of feedback from patient-reported outcome measurements to healthcare providers and patients in clinical practice*. Cochrane Database Syst Rev. , 2021. **10**(10).
24. Basch E, et al., *Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment*. JAMA Oncol., 2017. **318**: p. 197-198.
25. Basch E, et al., *Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial*. J Clin Oncol, 2016. **34**(6): p. 557-65.
26. Basch E, et al., *Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial*. Jama, 2022. **327**(24): p. 2413-2422.
27. Basch E, et al., *Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial*. JCO Clin Cancer Inform, 2020. **4**: p. 947-957.
28. Bedding C, et al., *Quality of life in metastatic breast cancer: A systematic review of psychosocial issues and adverse events*. Psycho-oncology, 2020. **29**: p. 25-25.
29. Basch E, *Patient-Reported Outcomes — Harnessing Patients’ Voices to Improve Clinical Care*. New England Journal of Medicine, 2017. **376**(2): p. 105-108.
30. Basch E, et al., *Implementation on of Patient-Reported Outcomes in Routine Medical Care*. American Society of Clinical Oncology Educational Book 2018. **38**: p. 122-134.
31. Thestrup Hansen S, et al., *Nurses’ Experiences When Introducing Patient-Reported Outcome Measures in an Outpatient Clinic: An Interpretive Description Study*. Cancer Nurs, 2021. **44**(2): p. E108-e120.
32. Stamm T, et al., *Building a Value-Based Care Infrastructure in Europe: The Health Outcomes Observatory*. NEJM Catalyst Innovations in Care Delivery, 2021.
33. de Ligt KM, et al., *International development of a patient-centered core outcome set for assessing health-related quality of life in metastatic breast cancer patients*. Breast Cancer Res Treat, 2023. **198**(2): p. 265-281.
34. Lizán L, Pérez-Carbonell L, and Comellas M, *Additional Value of Patient-Reported Symptom Monitoring in Cancer Care: A Systematic Review of the Literature*. Cancers (Basel), 2021. **13**(18).
35. Barbera L, et al., *The impact of routine Edmonton Symptom Assessment System (ESAS) use on overall survival in cancer patients: Results of a population-based retrospective matched cohort analysis*. Cancer Med, 2020. **9**(19): p. 7107-7115.
36. Carey EG, et al., *Editorial Perspective: When is a ‘small effect’ actually large and impactful?* Journal of Child Psychology and Psychiatry. **n/a**(n/a).
37. Pereira JL, et al., *Cancer Care Professionals’ Attitudes Toward Systematic Standardized Symptom Assessment and the Edmonton Symptom Assessment System After Large-Scale Population-Based Implementation in Ontario, Canada*. Journal of Pain and Symptom Management, 2016. **51**(4): p. 662-672.e8.
38. Graupner C, et al., *Patient outcomes, patient experiences and process indicators associated with the routine use of patient-reported outcome measures (PROMs) in cancer care: a systematic review*. Supportive Care in Cancer, 2021. **29**: p. 573–593.
39. Skovlund PC, et al., *The development of PROmunication: a training-tool for clinicians using patient-reported outcomes to promote patient-centred communication in clinical cancer settings*. Journal of Patient-Reported Outcomes, 2020. **4**(1): p. 10.

40. Sztankay M, et al., *Developing an e-learning course on the use of PRO measures in oncological practice: health care professionals' preferences for learning content and methods*. Support Care Cancer, 2022. **30**(3): p. 2555-2567.
41. Dutch Breast Cancer Patient Association (Borstkankervereniging Nederland), *Wat zijn jouw behoeften en ervaringen met begeleiding bij uitgezaaide borstkanker?* 2020.
42. Porter I, et al., *Integrating Patient Reported Outcome Measures (PROMs) into routine nurse-led primary care for patients with multimorbidity: a feasibility and acceptability study*. Health and Quality of Life Outcomes, 2021. **19**(1): p. 133.
43. Albers EAC, et al., *Visualization formats of Patient-Reported Outcomes in clinical practice: a systematic review about preferences and interpretation accuracy*. . Journal of Patient-Reported Outcomes (2022), 2022. **6**(18).
44. Subhan MA, et al., *Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type*. Cancers, 2023. **15**(8): p. 2204.
45. Loisel CG, *Now, more than ever, timing is right for oncology nurses to champion, co-design, and promote value-based and strengths-based cancer care!* Can Oncol Nurs J, 2023. **33**(2): p. 180-181.
46. Hartkopf AD, et al., *Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients*. JMIR Cancer, 2017. **3**(2): p. e11.
47. Mackert M, et al., *Health Literacy and Health Information Technology Adoption: The Potential for a New Digital Divide*. J Med Internet Res, 2016. **18**(10): p. e264.
48. Calvert MJ, et al., *Patient reported outcome assessment must be inclusive and equitable*. Nature Medicine, 2022. **28**(6): p. 1120-1124.

Figure 1 Goals for improvement of ABC patients

- 1 Help patients with ABC live longer by doubling ABC median overall survival by 2025
- 2 Enhance our understanding about ABC by increasing the collection of high quality data
- 3 Improve the quality of life (QoL) of patients with ABC
- 4 Ensure that all patients with ABC receive the best possible treatment and care by increasing availability of and access to care from a multidisciplinary team
- 5 Improve communication between healthcare professionals (HCPs) and patients with ABC through the provision of communication skills training for HCPs
- 6 Meet the informational needs of patients with ABC by using easy to understand, accurate and up-to-date information materials and resources
- 7 Ensure that patients with ABC are made aware of and are referred to non-clinical support services
- 8 Counteract the stigma and isolation associated with living with ABC by increasing public understanding of the condition
- 9 Ensure that patients with ABC have access to treatment regardless of their ability to pay
- 10 Help patients with ABC continue to work by implementing legislations that protects their right to work and ensures flexible and accommodating workplace environments

Reprinted with permission, copyright ABC Global Alliance